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ABSTRACT: We have investigated the expression of cell surface markers and leu-
cocyte cell adhesion molecules by immunohistochemistry in bronchial biopsies from
10 mild atopic asthmatics and 8 normal, nonatopic subjects.
Significantly increased numbers of eosinophils (p<0.01) were evident in the
bronchial submucosa of asthmatic subjects. In epithelium there were more CD44+
(p<0.02) and lymphocyte function-associated antigen-1 (LFA-1)+ (p<0.06) leuco-
cytes in asthmatics than in normal subjects. Bronchial epithelial cells stained pos-
itively with anti-CD44 monoclonal antibodies (moAb) in both groups; however,
when the staining was expressed as percentage of the total basement membrane,
a considerable and highly significant increase was observed in the asthmatics (medi-
an 80 vs 22%, p=0.003). Few leucocytes were positive for very late activation anti-
gen (VLA)-1, VLA-2 and VLA-4. The moAb for VLA-6 stained the basement
membrane of the bronchial epithelium; while intracellular adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) were constitutively
expressed in endothelium. A positive correlation was found between LFA-1+ cells
and activated eosinophils (EG2+) in the submucosa (p<0.005; rs=0.80). 
We conclude that even in mild asthma there is evidence of increased expression
of cell surface ligands, and suggest that adhesive mechanisms play a role both in
cell recruitment and disease activity.
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There is accumulating pathological evidence to imply
a role for chronic inflammation of the bronchial mucosa
in determining both the physiological abnormalities and
severity of atopic bronchial asthma [1–3]. In the process
of accumulation of inflammatory cells in the inflamed
mucosa, one of the primary steps is their infiltration into
the tissue, a phenomenon which is mediated by specific
interactions between cell surface molecules and their
endothelial ligands [4]. The mechanisms of cell-cell and
cell-matrix interactions involve increased expression of
cell adhesion molecules (CAMs) on the cell and vessel
surfaces [4]. Immunohistochemical studies of bronchial
biopsies have shown constitutive expression of several
CAMs, such as intercellular adhesion molecule-1 (ICAM-
1), a member of the immunoglobulin supergene family,
and E-selectin. a member of the selectin family [5]. In
support of the role for CAMs in allergic inflammation,
studies in monkeys have shown that allergen challenge
in Ascaris suum-sensitized animals results in upregula-
tion of ICAM-1 in parallel with an increase in bronchial
responsiveness, both of which can be abrogated by pre-
treatment with blocking anti-ICAM-1 antibodies [6].
Studies in mild asthma have shown that the expression
of ICAM-1 and E-selectin is not different from that in
healthy, nonatopic control subjects [5]; however, in per-
ennial rhinitis, where chronic inflammation may be more
severe, both ICAM-1 and the vascular cell adhesion
molecule-1 (VCAM-1) have been found to be upregu-
lated [7]. Furthermore, following local allergen chal-
lenge the number of mucosal blood vessels staining
positively with antibodies directed against ICAM-1 and
E-selectin increases severalfold [8]. When considered
together with the associated increase in inflammatory
cells expressing the lymphocyte function associated anti-
gen-1 (LFA-1), an integrin which acts as the ligand for
ICAM-1, these observations clearly implicate adhesive
mechanisms in cell recruitment into asthmatic bronchial
tissues [8].
Recently, studies of lymphocyte activation and cell-
cell and cell-matrix adhesion have converged on a broad-
ly distributed human cell surface glycoprotein known as
CD44 or Hermes antigen [9]. The CD44 molecule demon-
strates marked structural differences between tissues,
due to alternative splicing and variable glycosylation.
Although the standard form, containing no variant reg-
ions, is expressed on lymphocytes, CD44 isoforms have
been shown by complementary deoxyribonucleic acid
(cDNA) cloning and sequencing to be weakly expressed
in the normal epithelium and highly expressed in some
metastatic carcinomas, such as adenocarcinomas, and
on aggressive types of non-Hodgkin's lymphoma [10].
The CD44 binds to hyaluronic acid and is involved in
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the heterotypic recognition of high endothelial venules
(HEV), the specialized venules in lymphoid tissue that
mediate lymphocyte extravasation in the process of lym-
phocyte homing [9].
In order to further evaluate the distribution and possi-
ble role of adhesive molecules in allergic inflammation,
we have analysed the expression of CAMs in bronchial
biopsies obtained from atopic mild-to-moderate asth-
matic patients and healthy nonatopic control subjects
using immunohistochemistry. We have investigated the
expression of ICAM-1 and its ligand, LFA-1 and VCAM-
1 and its ligand, very late activation antigen (VLA)-4,
adhesion molecules for which a role in asthma patho-
genesis has been strongly suggested [7, 8]. We have ex-
tended the study of very late antigens to VLA-1 and
VLA-2 as markers of T-cell activation, since it has been
shown that VLA-1 is upregulated in acute exacerba-
tions of asthma [11], and also VLA-6, which is involved
with the α6-chain in the specific adhesive mechanisms
in the bronchial epithelium [12]. Because nothing is
known about the contribution, if any, of CD44 to asth-
ma pathogenesis, we have studied the distribution of
cells staining positively for this adhesion molecule and
its expression on the surface of epithelial cells.
To provide correlates between adhesion molecules
and inflammatory cell types, we have enumerated mast
cells, activated eosinophils and CD3+ lymphocytes, and
have related the cell counts to the level of expression
of CAMs.
Materials and methods
Subjects
Ten patients with mild to moderately severe asthma (5
females and 5 males; mean age 30 yrs, range 21–49 yrs)
and eight normal nonatopic control subjects (2 females
and 6 males; mean age 29 yrs, range 18–59 yrs) were rec-
ruited into the study. All the asthmatics had stable pulmo-
nary function, with a forced expiratory volume in one
second (FEV1) ≥70% of predicted. The median FEV1 was
88% (range 74–108%) for asthmatics and 96% (range
82–112%) for the normal subjects. All the asthmatics
were atopic as confirmed by skin prick testing with a
series of common inhalant allergens (Dermatophagoides
pteronyssinus, mixed grass pollen, cat fur, dog hair, fea-
thers, and a mixture of moulds; Bencard, Brentford, UK).
The asthmatics had mild-to-moderate airways respon-
siveness as assessed by the provocative concentration
of inhaled methacholine required to produce a 20% fall
in FEV1 (PC20) (geometric mean PC20 2.82, range 0.11–
25 mg·mL-1) [13]. In none of the normal control sub-
jects was it possible to induce a fall ≥20% in FEV1 with
the highest concentration of methacholine used (25
mg·mL-1). All the asthmatics used the β2-agonist salbu-
tamol as required for relief of symptoms. None of the
asthmatics had received any treatment with oral or in-
haled corticosteroids, sodium cromoglycate or nedocromil
sodium for at least three months prior to bronchoscopy.
All the subjects were nonsmokers and none had expe-
rienced an upper respiratory tract infection within 6
weeks of the study. The healthy volunteers had no his-
tory of asthma, were on no medication, and all had neg-
ative skin prick tests to the same range of allergens.
The study was approved by the combined Southampton
Hospitals and University Ethics Committee and all the
participants gave their written informed consent.
Bronchoscopy
All the procedures were performed using a fibreop-
tic bronchoscope (Olympus 1T20, Tokyo, Japan) accord-
ing to the National Institute of Health guidelines [14],
and as reported previously [15]. 
Monoclonal antibodies
The following mouse antibodies were used: 1) anti-
LFA-1 moAb, clone TS1-22 (a gift from T.A. Springer,
Boston, MA, USA); 2) anti-CD44 moAb, clone Hermes
3 (a gift from S. Jalkanen, Turku, Finland); 3) anti-
VLA-1 moAb, clone TS2/7 (a gift from T.A. Springer,
Boston, MA, USA); 4) anti-VLA-2 moAb, clone CLB
ThIV (a gift from the Netherland Red Cross, Amsterdam);
5) anti-VLA-4 moAb, clone CLB 485 (Cymbus Ltd,
Southampton, UK) and anti-VLA-4 moAb, clone HP1/2
(provided by R. Lobb, Biogen Ltd, Boston, MA, USA);
6) the clone GOH-3 against the α6-chain of the human
VLA-6 heterodimer (α6β1) (a gift from A. Sonnenberg,
The Netherlands); 7) anti-ICAM-1 moAb, clone RRI (a
gift from R. Rothlein, USA); 8) anti-VCAM-1 moAb,
clone 1.4C3 (a gift from D. Haskard, London, UK); 9) anti-
endothelium moAb, clone EN4 (San Bio, Netherlands);
(10) anti-mast cell tryptase moAb, clone AA1 (a gift
from A. Walls, Southampton, UK); 11) anti-eosinophil
cationic protein moAb, clone EG2; and 12) anti-CD3
moAb (Dako Ltd, High Wycombe, UK).
Processing of samples
The biopsy samples were processed into glycol metha-
crylate resin (GMA) (Polysciences, Northampton, UK)
and stored in airtight containers at -20°C [16]. The GMA
sections were cut 2 µm thick and two sections per moAb
were picked onto poly-L-lysine glass slides. The moAb
binding was displayed by peroxidase-labelled avidin-
biotin complexes, as described previously [15]. The stain-
ed slides were coded and examined using a Leitz Ortholux
2 microscope by one observer (DGP), who was not
involved in the patient care or biopsy procedure. In
each biopsy, the moAb positive cells were counted sep-
arately in the epithelium and in the submucosa. The
results were expressed as the number of cells per mil-
limetre of basement membrane in the epithelium and
per millimetre squared of submucosa in the subepithe-
lial tissue. The area of the submucosa was calculated
by delineating the area of the submucosa excluding the
glands and blood vessels on a Video Interactive Display
System (VIDS 2) and using AMS software (Analytical
Measurement Systems, Cambridge, UK).
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The expression of cell adhesion molecules in the
endothelium was evaluated as described previously [7].
In order to evaluate the accurate localisation of immuno-
reactivity, sequential 2 µm sections were obtained. One
section was stained for the presence of an endothelial
cell adhesion molecule and the adjacent section stained
with a vessel marker, EN4, to identify all the blood
vessels in the sections. The numbers of vessels stained
positively for the two adhesion molecules, ICAM-1 and
VCAM-1, in consecutive sections were expressed as a
percentage of the total number of vessels. Positive stain-
ing for any of the adhesion molecules in the epithelium
and basement membrane (bm) was expressed as a per-
centage of their total length.
Statistical analysis
All the immunohistochemical data are shown as medi-
an and range. The Mann-Whitney U-test was used to ana-
lyse differences between groups in cell counts and CAM
expression. The Spearman's rank coefficient was used
to investigate the relationship between the expression
of adhesion molecules and leucocyte phenotypes.
Results
Leucocyte phenotypes
The median (range) numbers of mast cells, identified
as AA1+ cells in the epithelium were 0.1 (0–2.4) cells·
mm-1 bm in the asthmatics and 0.25 (0–2.0) cells·mm-1
bm in the normal subjects (p>0.05). There were 54.5
(0.9–150.0) AA1 cells·mm-2 of submucosa (sm) and 55.7
(22.9–64.7) cells·mm-2 sm, in the asthmatics and nor-
mal subjects, respectively, with no significant differ-
ence existing between the two groups. When staining
for eosinophils with moAb EG2, which identifies "acti-
vated" cells, a significant difference (p<0.01) was ob-
served between the asthmatic patients (13.1 (4.1–195.2)
cells·mm-2 sm) and normal subjects (2.6 (0–16.1) cells·
mm-2 sm) in the bronchial submucosa (fig. 1), but not
in the epithelium (0.16 (0–1.6) and 0 cells·mm-1 bm,
respectively). There was no difference in the number of
CD3+ T-lymphocytes between the asthmatic patients
and normal subjects both in the epithelium (3.2 (0–26.6)
vs 5.5  (0–13.3) cells·mm-1 bm),  and submucosa (231.8
(10.5–650.0) vs 106.4 (57.8–276.8) cells·mm-2 sm) (fig.
1).
Expression of adhesion molecules
In the epithelium of asthmatics, there were signifi-
cantly (p<0.02) more leucocytes staining for CD44 than
in the normal controls (29.3 (5.9–94.3) and 6.6 (0–33.8)
cells·mm-1 bm, respectively) (fig. 2a). The CD44+ cells
were identified, according to their morphology, as lym-
phocytes, macrophages and eosinophils. In the submu-
cosa, no difference was observed for CD44+ leucocytes
between the asthmatics (45.7 (24.1–87.0) cells·mm-2 sm)
and control subjects (36.0 (4.1–92.0) cells·mm-2 sm)
(fig. 2b). CD44+ staining was also present on bronchial
epithelial cells in both groups, localized predominantly
around the apical and lateral sides of the basal cells, al-
though staining was also noted among the columnar
cells and between the basal cells and the basement mem-
brane (fig. 3). When the CD44 staining between the basal
cells and the basement membrane (expressed as the per-
centage of the length of the epithelium) was compared
between groups, a highly significant difference was
seen, with a median 80% (range 28–100%) of the bron-
chial epithelium staining positively in the asthmatics
compared to 22% (range 0–36%) in the controls (p=0.003)
(fig. 4).
In the asthmatic group, the LFA-1+ leucocytes in the
epithelium (10.8 (0–34.1) cells·mm-1 bm) were increased
by comparison with the normal subjects (3.35 (1.37–
14.5) cells·mm-1 bm), but this just failed to reach stati-
stical significance (p=0.06) (fig. 5a). No difference was
observed in the number of LFA-1+ cells in the submuc-
osa between the asthmatics (33.0 (10.9–101.2) cells·mm-2
sm) and controls (34.0 (2.0–57.9) cells·mm-2 sm) (fig. 5b).
2238
●
●
●
●
●●
●
400
300
200
100
0
80
60
40
20
0
Asthmatics Controls
●●
●●
●
●
●
●
●
p<0.01
(195)
●●
●
EG
2+
 c
el
ls
·m
m
-2
 in
 th
e 
su
bm
uc
os
a
●
C
D
3+
 c
el
ls
·m
m
-2
 in
 th
e 
su
bm
uc
os
a
●
Asthmatics Controls
●
●
●●
●
NS
(650)
●
●
●
●
●
●●
●
●●
a) b)
Fig. 1.  –  Numbers of: a) submucosal EG2+ activated eosinophils;
and b) CD3+ cells in the submucosa in asthmatics and control (nor-
mal) subjects. Horizontal lines denote median values. NS: statistical-
ly nonsignificant.
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Fig. 2.  –  Numbers of CD44+ cells: a) in the epithelium; and b) in
submucosa in asthmatics and control subjects. Horizontal lines denote
median values. NS: statistically nonsignificant.
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Few cells stained positively for the very late anti-
gens. In the epithelium, no positive cells were observed
when moAbs anti-VLA-1 and anti-VLA-2 were used.
In the submucosa, a few cells stained positively for
VLA-1 and VLA-2 both in the asthmatics (2.1 (0–4.3)
and 0 (0–3.4) cells·mm-2 sm), respectively) and normal
subjects (0.7 (0–0.25) and 0 (0–0.8) cells·mm-2 sm) (p>
0.05). No statistical difference was observed between
the asthmatic and normal subjects in the number of
VLA-4 cells, both in the epithelium (0 (0–1.5) vs 0.6
(0–4.6) cells·mm-2 bm) and submucosa (3.8 (0–10.0)
vs 1.3 (0–10.8) cells·mm-2 sm).
Using moAbs against VLA-4 from two sources, no
positive staining for the chain of VLA-4 was observed
in the basement membrane of the epithelium or blood
vessels. Although no VLA-6 positive staining of inflam-
matory or structural cells was seen, in both groups the
distribution of α6-chain was localized to the zone bet-
ween the basal cell layer and the basement membrane,
and in the wall of some vessels of the bronchial sub-
mucosa.
Staining for ICAM-1 was expressed constitutively in
the microvascular endothelium both of the asthmatic
(median 24% of blood vessels, range 0–69%) and nor-
mal biopsies (median 25% of blood vessels, range 0–
100%) (p>0.05). VCAM-1 was expressed at a very low
level in all biopsies (median 0% of blood vessels (range
0–5%) in the asthmatics, and 0% of blood vessels range
(0–3%) in the control group).
Relationship between adhesion molecule expression,
leucocyte phenotypes and clinical activity
When the expression of adhesion molecules was com-
pared with the number of leucocytes present in the
bronchial mucosa, a strongly positive correlation was
observed between LFA-1+ cells and EG2+ staining
eosinophils in the submucosa (rs=0.80; p<0.005). No
other correlations between the expression of the dif-
ferent adhesion molecules and infiltrating cell type was
found. No correlation was observed between the adhe-
sion data and the severity of disease activity.
Discussion
Using fibreoptic bronchoscopy to obtain bronchial
biopsies, and immunohistochemistry, we have studied
the leucocyte phenotypes and expression of CAMs in the
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Fig. 3.  –  Light microscopic micrograph of a bronchial biopsy taken
from an asthmatic subject, embedded in glycol methacrylate and
immunostained with monoclonal antibody (moAb) to CD44. Internal
scale bar = 10 µm.
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Fig. 4.  –  Percentages of bronchial epithelium staining for CD44 in
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an values. NS: statistically nonsignificant.
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bronchial mucosa of atopic asthmatic and nonatopic con-
trol subjects. As reported previously, a prominent eosi-
nophilia was seen in the bronchial mucosa of asthmatics
[15, 17], although no differences in the counts of lympho-
cytes and mast cells were observed [18]. Immunohisto-
chemical staining showed constitutive expression of all
the adhesion molecules studied, except for VLA-6 on
inflammatory cells. Whilst there was relatively abun-
dant staining for LFA-1, which was higher in the asth-
matics in the epithelium, only a few cells stained for
VLA-1, VLA-2 and VLA-4, with no difference between
asthmatics and normals. Staining for GOH-3 moAb,
recognizing the α6-chain of the integrins α6β1 (VLA-
6) and α6β4, was strongly displayed on the basement
membrane and basal layers of the epithelium, a find-
ing which is in keeping with the previous localization
of integrin α6β4 to hemidesmosomes [19–21].
Increased staining for the homing antigen, CD44, was
observed on leucocytes in the bronchial epithelium and
on epithelial cells of the asthmatic subjects. In keep-
ing with previous reports [22], and demonstrated by
using antibodies from different sources, we found no
staining for VLA-4 in the basement membrane of either
the epithelium or blood vessels. Basal expression of
ICAM-1 and VCAM-1 on postcapillary venules was
noted, although no difference was seen between asth-
matics and control subjects.
Although the number of cells staining for anti-LFA-1
was higher in the epithelium of asthmatic subjects, this
just failed to reach significance, possibly due to the mild
disease activity of the asthmatics studied. A positive cor-
relation between LFA-1+ staining and the number of
EG2+ eosinophils was observed, suggesting that in asth-
matics LFA-1 may be contributing to the migration of
activated eosinophils into the airways mucosa. In the asth-
matic biopsies of the present study there was a very large
number of CD3+ lymphocytes in submucosa but very
few cells positive for LFA-1, that is thought to be exp-
ressed on all leucocytes. A possible explanation could
be the different status of activation of the CD3+ cells,
since it is well recognized that the CD45RO+ T-lympho-
cyte subpopulation, which exhibits antigen recall, has a
greater constitutive expression of LFA-1 than do naive
T-cells (CD45RA+) [23], and lymphocyte activation is
known to upregulate LFA-1 expression [24].
The CD44 antigen, originally identified as the lym-
phocyte homing receptor and termed Hermes antigen,
has been shown to be responsible for binding of lym-
phocytes to hyaluronic acid [9]. The moAb used in this
study, Hermes-3, was produced by immunization with
affinity isolated antigen from mucosal-specific cells and
recognizes the same glycoprotein defined by Hermes-
1. It inhibits lymphocyte binding to mucosal HEVs and
not to lymph node or synovial HEVs [9]. More recent-
ly, CD44 distribution has been extended to nonlym-
phoid tissue, such as fibroblasts, smooth muscle cells
and the bronchial and alveolar epithelium [25]. The role
of this molecule is still debated: it is thought to be
involved in several steps of normal immune cell func-
tion, such as lymphocyte adhesion to HEV [26] and the
extracellular matrix, as well as in T-cell activation [27].
It has been shown that triggering of CD44 on T-lym-
phocytes by anti-CD44 moAb can promote cell adhe-
sion via the LFA-1 pathway [28], and induce resting
peripheral blood lymphocytes to proliferate in the pres-
ence of phorbol esters [29]. The CD44+ leucocytes were
identified as lymphocytes, macrophages and eosinophils
according to their morphology. However, these obser-
vations were sustained by the use, in some specimens,
of camera lucida technique, which makes it possible to
identify cell localization using two moAbs in adjacent
sections of the biopsy [16].
The bronchial epithelium also showed strong expres-
sion of CD44, which was at a significantly higher level
in the asthmatics than controls. The staining was dis-
tributed around the periphery of the bronchial epithe-
lial cells both in normal subjects and asthmatics. Unlike
the other markers, CD44 was also expressed as a per-
centage staining per millimetre of basement membrane;
the CD44 epithelial cell staining was strong and diffuse
between the basal cells and the basal membrane. Most
recently, we have utilized immunoelectronmicroscopy
to quantify CD44 expression in the bronchial epitheli-
um of normal and asthmatic subjects, and have con-
firmed an asthma-related upregulation [30]. The diffuse
presence of CD44 in the normal epithelium suggests
that this glycoprotein is involved in the normal adhe-
sion between structural cells, but its upregulation on
inflammatory cells and in the epithelium in asthma indi-
cates a possible role in cell recruitment and in epithe-
lial repair. The much broader tissue distribution of CD44
suggests that it promotes a type of adhesion which is
exploited by a wide variety of cells [10].
As we have reported previously, ICAM-1 was pre-
sent constitutively in about 30% of the postcapillary
venules of the airways mucosa [5], and the distribution
in asthmatic subjects was not different from that in
nonatopic control subjects [5], a finding that may be
explained by the mild disease of the subjects studied.
The family of integrins represents a group of trans-
membrane glycoprotein receptors, consisting of non-
covalently associated α and β subunits [4, 19, 22].
Although several studies have investigated the expres-
sion of integrins in cell cultures [19, 22], little is known
about their distribution in diseased lung tissue [31], and
it remains unclear to what extent the integrins are cru-
cial to the allergic inflammation in atopic asthma. The
β2-integrin LFA-1 (CD11a/CD18), which is the leuco-
cyte ligand for ICAM-1, was expressed on more cells
in the asthmatics than in control subject but, possibly
because most of the subjects experienced only mild-to-
moderate asthma, the increase in LFA-1+ leucocytes
just failed to reach significance. We have previously
found an increase in LFA-1+ staining cells in the airway
wall after local allergen challenge in asthmatics with
disease activity that was comparable to that of the sub-
jects in the present study [8]. Since LFA-1 is expressed
on almost all leucocytes, it is considered to be an index
of the total number of infiltrating inflammatory cells.
Thus, the increased number of LFA-1+ cells in the pre-
sent study reflects a general increase in leucocytes. This
heterodimer plays a role in leucocyte-leucocyte inter-
action and leucocyte-endothelial cell adhesion. In addi-
tion, LFA-1 expression is upregulated on activated
lymphocytes [24]. The number of cells staining posi-
tively for this adhesion molecule has also been found
to be elevated in perennial rhinitis and to correlate with
the degree of neutrophil infiltration [7]. In the present
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study, we have found a positive correlation between
LFA-1 and the number of activated eosinophils, a find-
ing which is in keeping with the eosinophilic nature of
the cellular infiltrate in the lower airways in asthma.
Very few cells stained for VLA-4, the ligand for
VCAM-1. In order to reduce any doubt on the sensitiv-
ity of our method, we used antibodies from two different
sources; however, immunostaining of cells was low with
both the moAbs used, even if the EG2+ and CD3+ cell
counts were high. The same remark extends to VLA-6
and eosinophils in the submucosa. However the mech-
anism for eosinophil and lymphocyte recruitment in as-
thmatic airways involves a number of overlapping steps.
A previous study by our group [8] suggested an upreg-
ulation of E-selectin and ICAM-1 but not VCAM-1 (the
VLA-4 ligand) after allergen challenge. However, it is
likely that the extent of VCAM-1 expression is too low
to be detected by simple immunohistochemistry when
compared to the marked upregulation of E-selectin and
ICAM-1 that occurs in the presence of cytokines that
regulate these adhesion molecules [32]. In keeping with
previous reports, immunostaining for the integrins VLA-
1 and VLA-2 identified very few positive cells, and no
cellular staining for VLA-6 [31]. Staining for integrin
α6β4, a component of hemidesmosomes, was localized
to the basement membrane of the epithelium and sub-
mucosal vessels, as described previously in the cornea
and skin [33, 34]. In acute exacerbations of asthma,
VLA-1 has been shown to be upregulated on periph-
eral blood T-cells [11], and the low expression of these
integrins in the mucosa in the present study is proba-
bly the consequence of the mild disease activity.
In conclusion, this study has provided evidence for
the constitutive expression of several adhesion mole-
cules in the epithelium and submucosa of normal air-
ways, and upregulation of CD44 and LFA-1 in the
bronchial mucosa in mild asthma suggestive of their
role in facilitating leucocyte recruitment and activation.
The observation of staining for CD44 in extracellular
sites is novel and clearly requires further elucidation.
Our data show that in this study population of atopic
patients with mild asthma there were more eosinophils
and other leucocytes than in the controls, rather than
an increased expression of the ligands. Further studies
are necessary to obtain specimens from patients with
severe asthma in order to verify whether the staining
for CD11a and β1-integrins will be expressed more
strongly and to investigate alternative adhesive mech-
anisms on the leucocytes.
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